Clinical Trial VICCBMT1071


Targeted Therapy for Bronchiolitis Obliterans Syndrome (BOS)

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCBMT1071
  • Open Date: 08/01/2011
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To determine if the combination treatment of inhaled fluticasone, azithromycin, and montelukast (FAM) administered in post Hematopoietic Cell Transplantation (HCT) recipients after the diagnosis of new onset bronchiolitis obliterans syndrome (BOS) can decrease the rate of treatment failure relative to an estimated historical rate of 40% using current therapies
  • Disease Sites: Hematologic
  • Therapies: Supportive Care
  • Drugs: Azithromycin; Fluticasone; Montelukast; Prednisone
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01307462
  • Secondary Protocol No: RDCRN-6503



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.